Pink Sheet Podcast: Sarepta DMD Gene Therapy Issues, New COVID-19 Vaccine Schedule, Medicare Price Negotiation
Executive Summary
Pink Sheet reporters and editors discuss questions about Sarepta’s Duchenne muscular dystrophy gene therapy candidate, the US FDA’s efforts to simplify the COVID-19 vaccine schedule, and industry’s ideas for Medicare price negotiation system changes.
You may also be interested in...
BIO Notebook: Waiting On Data, Adjusting To The IRA, And Focusing On All Patients
GSK, BridgeBio, and the US FDA’s patient-focused drug development director discuss contingency planning as the BIO International Convention concludes in Boston.
BIO Notebook Day 4: Waiting On Data, Adjusting To The IRA, And Focusing On All Patients
GSK, BridgeBio, and the US FDA’s patient-focused drug development director discuss contingency planning as the BIO International Convention concludes in Boston.
BIO Notebook Day 3: Venture Capital Musical Chairs, Pfizer’s Financing Strategy, And Boehringer on Being The Early Bird
Plus, Roche talks about why it wants to partner with firms that have machine learning expertise as the BIO International Convention continues in Boston.